While glucagon-like peptide (GLP)-1 receptor agonists have been successfully used in the treatment of diabetes for some time, there are now agents that activate not only the GLP-1 receptor but also the glucose-dependent insulinotropic polypeptide (GIP) receptor. Dual GLP-1/GIP agonists are considered promising new drugs for the treatment of obesity and type 2 diabetes.
This content is machine-translated. Please contact us if you need professional translation services.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Cardiovascular risk in IBD
Cause for concern?
- Microplastics in kidneys and urine
Life in plastic … is not fantastic
- Asthma and psyche
When fear makes you lose your breath
- COPD: Update for the primary care physician
Counteract exacerbations and improve quality of life
- Stroke
Not on the brain – the latest findings on strokes
- Atopic dermatitis: choice of systemic therapy option
“It’s always an individual weighing”.
- Do low carb diets harm the heart?
Keto diet associated with hypercholesterolemia and increased risk of ASCVD
- Cardiovascular events in CKD